Business
Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
– Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n– Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and conditioning pipeline –\n\n– Oral presentation of completed Phase I clinical trial confirms that MGTA-145, a novel biologic, robustly mobilized large numbers of functional hematopoietic stem cells (HSCs) for autologous and allogeneic stem cell transplant – \n\n– Additional preclinical data of MGTA-145 demonstrated successful collection of HSCs, mediating potential enhanced engraftment and reduced GvHD in models compared to G-CSF mobilized stem cells –\n\n– Preclinical data from a study of MGTA-117, an ADC that targets CD117, demonstrate that it is an effective, potent conditioning agent with anti-leukemia activity with the potential to improve transplant outcomes in patients with acute myeloid leukemia (AML) – \n\n– Preclinical data from a study of Magenta’s CD45-ADC conditioning agent demonstrate ability to achieve complete chimerism in fully mismatched allogeneic hematopoietic stem cell transplant (HSCT), potentially offering a reduced toxicity single agent conditioning regimen –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held December 5-8, 2020.\n\n“These data demonstrate the progress of our clinical and preclinical pipeline to expand patient eligibility to safely and effectively benefit from a potentially curative stem cell transplant,” said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta Therapeutics. “Our ASH presentations give insight into the significant impact our mobilization and conditioning programs stand to make for a broad range of patient populations. We look forward to advancing this pipeline further in 2021, with several anticipated data milestones ahead.”\n\nOral Presentation Showcasing Clinical Data of MGTA-145 Stem Cell Mobilization Program: \n\nMagenta is developing MGTA-145 to be the first-line therapy for same-day mobilization and collection of hematopoietic stem cells (HSCs) for transplant, to enable succ...